The European Commission has granted marketing authorization for cefiderocol, an innovative antibiotic developed by Shionogi, to address serious infections caused by multidrug-resistant Gram-negative bacteria. This approval follows a positive opinion from the European Medicines Agency (EMA) and is aimed at providing clinicians with an additional treatment option for patients with limited alternatives.

Cefiderocol is indicated for the treatment of infections such as complicated urinary tract infections, hospital-acquired pneumonia, and bloodstream infections. Its unique mechanism of action allows it to overcome resistance mechanisms that render many other antibiotics ineffective, making it a valuable addition to the antimicrobial arsenal in European hospitals.

The approval is part of ongoing efforts by European health authorities to address the growing threat of antimicrobial resistance (AMR). Healthcare professionals are encouraged to use cefiderocol in accordance with antimicrobial stewardship principles to preserve its effectiveness for future patients.